Noninvasive early detection of breast cancer through the use of biomarkers is urgently needed since the risk of recurrence, morbidity, and mortality is closely related to disease stage at the time of primary surgery. A crucial issue in this approach is the availability of relevant markers and corresponding monoclonal antibodies suitable for the development of effective immunodiagnostic modalities. The identification of such markers from human pathological lesions and the isolation of specific antibodies using conventional approaches remain major challenges. Camelids produce functional antibodies devoid of light chains of which the single N-terminal domain of the heavy chain is fully capable of antigen binding. When produced as an independent domain, these so-called single-domain antibody fragments (sdAbs) or nanobodies have several advantages for biotechnological applications owing to their unique properties of size (13 kDa), stability, solubility, and expression yield.
Introduction
Breast cancer is the most common cancer among women in Western countries. In France, 41,000 new cases are diagnosed each year and 25% of these women are below the age of 50. Breast cancer has a heterogeneous behavior and the frequency of metastasis in regional lymph nodules depends on tumor types 1 of patients with metastatic breast cancer 5 . Measuring HER-2 is important for selecting optimal therapy and predicting prognosis in breast cancer patients. Current methods for evaluating HER-2 include the detection of shed antigen in the serum by enzyme-linked immunosorbent assay (ELISA) 6 , or the analysis of protein overexpression by IHC. IHC is now frequently used in the evaluation of many epithelial proliferations. Improved antigen retrieval techniques and a better understanding of biology have contributed to the broader utility of IHC for solving everyday diagnostic problems in breast pathology 7 .
In addition, new emerging antibody based approaches are now in development for breast cancer diagnosis. For example, microarray multiplex protein measurement of biomarker-based molecular diagnostic and prognostic cancer testing assays is destined to become a large growth segment of the immunodiagnostic industry. Protein microarrays are among the novel class of rapidly emerging proteomic technologies that might lead to efficient and specific diagnosis 8 . Microbead protein arrays use surface-coupled capture molecules and flow cytometry to simultaneously quantify several antigens. Multiplexing is achieved by either using different sized microbeads or color coding that is readable by a laser-induced fluorescent detection system 9 . This latter approach is suitable for the analysis of up to a hundred different bead-bound antibodies and/or proteins in a complex mixture. These assays can be directly compared to ELISA method 10 , but they require smaller volumes of sample material, and can be multiplexed. Thus bead array represents the method of choice for low density antibody array for clinical use such as diagnosis or prognosis 11, 12 . This technique has the potential to generate non invasive and high throughput assay for screening and follow-up of large populations of women.
Another emerging and interesting diagnostic approach is the detection of circulating tumor cells (CTC) as an indicator of metastatic disease. Their detection is expected to provide a powerful tool for cancer prognosis, diagnosis of minimal residual disease, assessment of tumor sensitivity to anticancer drugs, and personalization of anticancer therapy 13 . CTC detection in blood samples may also be used to diagnose cancer and monitor a patient's response to therapy. Since CTCs are rare, comprising about one tumor cell among billions of normal blood cells in advanced cancer patients 14 , their detection and enumeration is a difficult task. Breast cancer circulating tumor cells are typically extracted from circulation through positive selection using epithelial cell-adhesion molecule (EpCAM), or HER2 as markers, leading to currently unknown biases when cells are undergoing epithelial-to-mesenchymal transition 14 .
To increase the specificity of this assay, one solution could be to use a large panel of antibodies targeting several membrane tumor antigens.
All this approaches are dependent on the availability of a variety of specific monoclonal antibodies (mAb). Unfortunately, it is not always easy to identify non-cross reactive mAbs against a large variety of markers. Moreover, their high production cost and their stability after immobilization are limiting factors for the development of some diagnostic assay 15, 16 . , a high solubility, and high expression yields 22 . Phage display technology has been extensively used to isolate tumor specific antibodies able to bind their cognate antigens in the cellular context [23] [24] [25] [26] [27] [28] [29] . It can be used to isolate binders against tumor specific markers [30] [31] [32] [33] [34] [35] .
In this study, we have used phage display to isolate several relevant anti tumor markers sdAbs from immunized libraries. The straightforward use of these sdAbs for diagnostic approaches are also presented, including conventional assays such as ELISA or IHC, but also more innovative approaches such as multiplexed analysis of a complex sample by cytometric bead array (CBA) and the enrichment of rare cells in a complex sample by magnetic beads followed by flow cytometry characterization.
Results

Selection of phage antibodies
Phage display was used to isolate antibodies against breast cancer specific targets. Various selection strategies were performed to obtain sdAbs against known and unknown targets.
Selection of anti-HER2 sdAbs
Although breast cancer is a very heterogeneous disease, 20-30% of tumors overexpress the human epidermal growth factor receptor 2 (HER2) 36 . SdAbs against this target are thus highly relevant for a diagnosis approach. To isolate such sdAbs, a llama was immunized with HER2-expressing ovarian cancer cell line SKOv3 and a sdAb library was built and used to perform biopannings. The first round of selection was performed on purified recombinant HER2 ectodomain fused to a human Fc portion (HER2-Fc) followed by a second round on HER2-positive SKBr3 cell line. After selection, 188 clones were screening and 92 clones were found positive by ELISA on HER2 positive cells (data not shown). Twenty clones were analyzed by sequencing, and all of them corresponded to a unique clone named C7b. The fine specificity of this clone was confirmed by ELISA (Fig. 1A) . SdAb C7b specifically bound to HER2-Fc fusion but not to an irrelevant Fc fusion, demonstrating its specificity for the HER2 ectodomain. Next, we used a flow cytometric based assay 37 to determine the affinity of this sdAb on cells naturally overexpressing HER2, and compared to the affinity of a dimeric version of this sdAb (obtained by Fc fusion and called C7b-Fc) and to the FDA-approved anti-HER2 monoclonal antibody (Herceptin/trastuzumab) (Fig. 1B) . The precise KD values were determined using the non-linear curve fitting program Prism (GraphPad) The affinity of the monovalent sdAb was 7 nM, 11-fold less than the bivalent herceptin affinity determined in parallel (600 pM). However, the measured affinity of C7b-Fc, a bivalent format of sdAb C7b directly comparable to Herceptin (bivalent IgG), was 200 pM, i.e. threefold higher than the one of Herceptin (Fig. 1B) . To confirm the affinity of sdAb C7b using an independent approach, a competitive ELISA using recombinant HER2-Fc antigen in solution was set up.
The calculated K D of 5.3 nM (Fig. 1C) was in close agreement with the flow cytometry data.
Finally, we performed a competition analysis by flow cytometric assay between sdAb C7b
and Herceptin (Fig. 1D) . A large excess of Herceptin could not compete out sdAb C7b, demonstrating that these two molecules do not share their epitope. .
A SDS-PAGE analysis of the immunoprecipitation revealed several strong specific bands in the 50 kDa range (Fig. 3A) . Mass spectrometry analysis of these bands identified the precipitated proteins as cytokeratin 19 (KRT19). The nature of KE9 antigen was confirmed by sandwich ELISA using KE9 as capture antibody, an anti-KRT19 mAb as detecting reagent and purified commercial KRT19 as antigen (Fig. 3B) .
Immunohistochemistry assays using single domain antibodies
IHC is a common procedure performed that has acquired an increasingly prominent role in the diagnosis of breast pathology. To evaluate the efficiency of the selected single domain
antibodies in IHC, we tested their reactivity on frozen embedded ductal breast cancer tissues (unrelated to biopsies used for immunization). As shown in 
Multiplexed analysis using single domain antibodies immobilized on fluorescent beads
This straightforward selection approach by phage display opens the possibility to rapidly select a variety of binders against various cancer samples and use the selected binders as binding unit to establish highly sensitive and quantitative diagnostic approaches. Therefore, we aimed at using the previously characterized binders to elaborate a multiplexed diagnostic assay for complex but precious samples such as biopsy lysates or patient serum. comparison with a standard curve obtained with the purified antigen (data not show). All four antigens were simultaneously detected using the corresponding mAb for known targets or by phage-sdAb (KE32) for the unknown target. As seen in Fig. 5A , all antigens could be simultaneously detected with high sensitivity using a small amount (50 µL) of complex sample.
Magnetic enrichment of rare cells using single domain antibodies
Streptavidin microbeads (Miltenyi Biotech) compatible with MACSQuant magnetic columns were used to evaluate the potential of biotinylated sdAbs as capture reagent for the enrichment of rare cells. As a proof of concept, anti-HER2 sdAb C7b was used to enrich breast cancer cells (SKBr3) from a large excess of human PBMC. A SKBr3:PBMC ratio of 3x10 3 : 6x10 6 was chosen to mimic the proportion of CTC in blood. The enrichment was monitored by following the percentage of HER2 positive cells using Herceptin. This simple procedure led to 276-fold enrichment of tumor cells compared to the initial ratio (Fig. 5B) .
Impressively, more than 97% of HER2 positive cells could be retrieved despite the 2 000-fold initial excess of PBMC.
Discussion
In this paper, we describe the selection of anti-tumor marker sdAbs and their straightforward use in several applications. Using the same library generated by immunization of llama with breast cancer biopsies, we selected sdAbs against known and relevant antigens such as HER2, or various sdAbs against unknown targets. Finally, some of these sdAbs were used to elaborate a sensitive and specific multiplexed assay on CBA to analyze a complex breast cancer representative sample. Other applications such as classical immunohistochemistry and an efficient and specific immune-enrichment of rare cells are also
shown.
Surprisingly, a direct coating of cell lysates used for selections on maxisorp 96 well plates could be used to characterize the binding specificity of selected clones against a wide range of cell line and biopsy lysates. The high complexity of these lysates and the possible conformational changes of antigens due to the adsorption process might have prevented the generation of high signal for the monoclonal phage ELISA screening assay. We found that most selected phage clones could properly bind their antigens in these conditions. Bound phage were detected using an HRP-labeled monoclonal antibody directed toward p8, present at around 2800 copies per phage particle and allowing a considerable signal amplification. As such, phage ELISA on immobilized lysates represents a sensitive, robust, inexpensive and HT-compatible reverse phase array assay that can be exploited to test hundreds of binders against dozens of cell lysates. This approach could be used to generate antigenic profiles of various cancer related samples including cell line, biopsies or fluids such as serum samples.
We have shown the possibility to identify the antigen recognized by the selected phage-sdAbs. In a previous work, we had demonstrated the feasibility to produce active sdAbs in the cytoplasm of E. coli, fused to the avitag, a 15 aminoacid sequence which is biotinylated on a single lysine by E. coli enzyme BirA. This approach allows the efficient and inexpensive production of biotinylated sdAbs which can be directly immobilized on streptavidin coated surfaces such as plates or beads, in a near covalent and oriented fashion 38 .
Here we have used this approach to immobilize sdAbs on magnetic streptavidin beads to immunoprecipitate the corresponding antigen. This approach was significantly more efficient than other ones, including the use of in vitro biotinylated sdAbs with streptavidin beads, his 6 -sdAbs with cobalt chelating beads, or direct covalent coupling of sdAb to epoxy beads (data not show). As proof of concept, the target of phage-sdAb KE9 was identified as cytokeratin 19 (KRT19). KRT19 is a relevant antigen for breast cancer analysis and is already used for immunohistochemistry analysis 40 , as tumor marker for serum analysis 41, 42 and for circulating tumor cells detection 43 . This result suggests that the proposed approach is capable of leading to the discovery of new relevant cancer related targets and biomarkers.
The in vivo biotinylation approach was also used to generate a sensitive multiplexed cytometry bead array. This assay can be directly compared to ELISA method 10 , but requires smaller volumes of sample material, and can be multiplexed. Thus bead array represents the method of choice for low density antibody array for clinical use such as diagnosis or prognosis 11, 12 . SdAbs have a tendency to bind cryptic epitopes normally inaccessible to conventional antibodies 25 . The anti-HER2 sdAb or the anti-KRT19 sdAb selected in this work seem to follow the same trend since they do not compete with trastuzumab or a commercial anti-KRT19 mAb, respectively. This characteristic facilitates the design of sandwich assays once the antigen is identified. Because we used in vivo biotinylation leading to the addition of a single biotin at the C-terminus of sdAbs, we could use fluorescently coded streptavidin beads that were coupled to a single sdAb before being mixed and incubated with the sample. Thus, the combination of phage display and single domain antibody technology appears as an attractive approach to rapidly generate a variety of binder whose characteristics are especially well adapted to the generation of inexpensive but powerful diagnostic tools for breast cancer diagnosis.
Materials and methods
Proteins sdAb CEA17 was previously described 25 .
Herceptin is a kind gift of Daniel Olive (CRCM, Marseille, France)
Plasmid pET-14b was used to produce in vivo enzymatically biotinylated sdAbs. All sdAbs produced in this vector carry a C-terminal his 6 -tag, preceded by the Avitag TM (GLNDIFEAQKIEWHE). For generation of plasmids coding for sdAb-avitag TM -his 6 , see 38 .
To subclone sdAbs isolated by selection in pHEN1-PhoA-6HisGS plasmid 44 in plasmids coding for sdAb-avitag TM -his 6 38 , sdAb was first amplified from pHEN1-sdAb-myc-his 6 using primers pHENpETAvirev (CGTTCAGACCTGCGGCCGCTGAGGAGACAGTGACCTGG) and pHENpETAvifor (CTTTAAGAAGGAGATATACCATGGCCGAGGTGCAGCTGGTG). Vector pET-sdAbaNef -avitag-his 6 was digested with NcoI and NotI and purified. Cloning by recombination was performed with InFusion™ Advantage PCR Cloning Kits (clontech) as recommended by the manufacturer. All constructs were verified by nucleotide sequencing.
To subclone sdAbs isolated by selection (in pHEN1 plasmid) in plasmids coding for sdAb-Fc (Fc from human IgG1), sdAbs were first amplified from pHEN1-sdAb-myc-his 6 using primers 5HLsecVHH (GGTTGCGTAGCTGAAACCGGTGAGGTGCAGCTGGTG) and 3VHHendH
(CGGTGGGCATGTGTGAGTTTTGTCTGAGGAGACGGTGACCTG). Vector pHLsec-sdAb-Fc was digested with
AgeI and BstEII and purified. Cloning by recombination was performed using In-Fusion™
Advantage PCR Cloning Kits (clontech) as recommended by the manufacturer. All constructs were verified by nucleotide sequencing. Biopsies or cells were lysed with a potter in lysis buffer : 150 mM NaCl, 1% Triton X-100, 50
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mM Tris HCl pH8 with protease inhibitor cocktail (Complete, Roche). The lysate was centrifuged 10 min at 13000 g at 4°C. Supernatant was the final cell lysate. Total protein concentration (average between 2-5 mg/ml) was determined spectrophotometrically using a protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
Production, purification and in vitro biotinylation of sdAbs
Production and purification procedures of in vivo biotinylated sdAbs was performed as described 38 .
In vitro biotinylation of protein was performed using Ez-link micro NHS-PEO4-biotinylation kit (Perbio science) following the recommendation of the manufacturer.
Llama immunization and library construction
Three young adult llamas (Lama glama) were immunized subcutaneously at days 1, 30, 60, 90
and 120 with breast cancer biopsy lysate (4701, 4952) or with healthy breast biopsy (one biopsy lysate per animal). One llama was immunized with 50 million of SKOv3 cells which strongly express HER2. VHH library construction was performed as described 25, 45 . Briefly, genes coding for VHH were amplified by RT-PCR from the total RNA of peripheral blood mononuclear cells isolated by ficoll gradient, and cloned into phagemid pHEN1.
Selection of phage-sdAbs
Phage-sdAb library was produced as described in 25 using KM13 helper phage.
Different strategies of panning were performed. Phage selection were performed using antigen-coated magnetic epoxy beads (Dynabeads, invitrogen, following recommendations of the manufacturer), using 96-well maxisorp plate (Nunc) coated with antigen overnight at 4°C, or using 2x10 6 intact cells.. Beads, plate or cells were washed three times in PBS (using a magnetic particle concentrator for magnetic beads and centrifugation step for cells). PhagesdAb library (1 ml) and beads, cells or plate were saturated in milk PBS 2%. For selection including a depletion step, phage-sdAb libraries were incubated with depletion support with rotation during 2 h at room temperature or at 4°C for cells. Phage-sdAb libraries (depleted or not) were recovered and incubated with beads or plate with rotation during 2 h at room temperature or at 4°C for cells. Next, beads, cells or plate were washed ten times with 1 ml of PBS 0,1% Tween (without tween for cells) and twice with PBS. Phage fixed on beads, cells or plates were eluted with tryspin solution (Sigma) at 1 mg/ml during 30 min at room temperature with rotation. Eluted phages were treated as described in 25 .
ELISA assays ELISA on epoxy beads
HER2-Fc or human Fc (R & D systems) were immobilized on magnetic epoxy beads (Dynabeads, invitrogen) during 48 h at 4°C following recommendation of the manufacturer.
For ELISA, 2 µl of beads/well were used. Beads were blocked with 5% milk-PBS (MPBS)
for two hours at RT. Beads were washed and incubated for 1h at RT with 50 µl of 2% MPBS containing in vivo biotinylated sdAbs CEA17 or C7b at 10 µg/ml or HRP-conjugated anti-Fc mAb at 1 µg/ml. After three washes with PBS, beads with sdAbs were incubated with HRPconjugated streptavidin (Jackson) (1 µg/ml) in 2% MPBS for one hour at RT. After three washes in PBS, bound antibodies were detected using ABTS. Coloration was followed at 405 nm.
Competitive ELISA on epoxy beads for affinity determination
A fixed concentration of in vivo biotinylated sdAb C7b (2 µg/mL) was added to serial dilutions of soluble HER2-Fc antigen (fivefold dilutions starting from 1.25 µM). After 1 h of incubation at RT, the remaining free fraction of biotinylated sdAb C7b was measured by incubating the mixture with 2 µl of HER2-Fc immobilized beads per well (prepared as above)
for 30 min at RT. After washing, bound sdAbs were detected as above. Dissociation constant was calculated using the non-linear curve fitting program Prism (GraphPad).
Phage-sdAb ELISA with lysate for screening and profiling
Monoclonal phage-sdAbs were produced as described in 25 .
Phage-containing supernatants were tested for binding by ELISA. with PBS Tween 0.1% and three washes in PBS, bound secondary antibodies were detected using ABTS. Coloration was followed at 405 nm.
ELISA using a couple of sdAbs
Streptavidin plates (Thermo scientific) were blocked with 5% milk-PBS (MPBS) for two hours at RT. Fifty µl/well of in vivo biotinylated sdAb at 10 µg/ml in 2% MPBS were incubated overnight at 4°C. Wells were washed and incubated for 1h at RT with 50 µl of 2% MPBS containing cell (BT474, SKBr3, HCC1954, MCF7, MDA-MB-231, T47D, HCC1806, BRCA-Mz-01, HCC1937, HME1, MC38, PBMC) or biopsy (5734, 5772ext, 5712, 5586, 5766, 5801, 5572int, 5592, 5627, 5011, 5033, 5713) lysates at 100 µg/ml of total proteins.
After three washes with PBS tween 0.1% and three washes in PBS, plates were incubated 1 h at RT with 25 µl/well of phage-containing supernatants mixed to 25 µl/well of 4% MPBS.
Following three washes with PBS tween 0.1% and three washes in PBS plates were incubated with HRP-conjugated anti-M13 mAb diluted 1/5000 for 1 h at RT. After three washes with PBS Tween 0.1% and three washes in PBS, bound secondary antibodies were detected using ABTS. Coloration was followed at 405 nm.
Flow cytometry analysis
Experiments were performed on ice with rocking in 1% BSA PBS. Typically, 2x10 5 
In-gel digestion and MALDI-TOF MS.
Protein spots excised from Coomassie blue (Imperial Protein stain, Pierce) stained gels were subjected to in-gel digestion with trypsin (Sequencing grade modified porcine trypsine;
Promega, Madison, WI, USA) according to a modified protocol from Shevchenko et al. 46 .
Tryptic peptides were then extracted from the gel, pooled and dried in a Speedvac evaporator.
Mass analyses were performed on a MALDI-TOF-TOF Bruker Ultraflex spectrometer 
Immunochemistry assay
in vivo biotinylated nanobodies were tested in immunostaining on 5 µm sections of frozenembedded cancer tissus. Endogenous peroxidase activity was blocked by incubation with 3% H 2 O 2 . Slides were incubated for 1 h with 10 µg/ml of in vivo biotinylated nanobodies at RT.
Detection was performed by incubations at RT for 30 min with streptavidin peroxidase.
Visualization was performed by DAB revelation (Dako) peroxidase reaction with haematoxylin as counterstain.
CBA assay
Three types of CBA Functional Bead system (BD Biosciences) were used for the assay.
The Functional Bead Conjugation Buffer Set was used for conjugation of streptavidin to beads following the recommendation of the manufacturer.
For multiplexed assay, 1. Negative controls (secondary antibody only) were carried out.
Rare cells enrichment assay
The enrichment procedure was performed using Streptavidin Microbeads (Miltenyi Biotech)
following the recommendation of the manufacturer. Capture antibody was in vitro biotinylated sdAb C7b at 10 µg/ml. Detection antibody was Herceptin labeled with Alexa660 at 10 µg/ml. Labeling was performed using Alexa Fluor® 660 Protein Labeling Kit (Molecular Probes, Invitrogen) following the recommendation of the manufacturer. We used a ratio of 3 000 SKBr3 cells mixed with 6 000 000 of human PBMC. cancer specific targets in a complex sample using a CBA assay. CBA beads were coated with streptavidin and incubated with in vivo biotinylated sdAb C7b, CEA17, KE9 or KE23. All beads were mixed and incubated with serial dilutions of serum containing CEA (starting concentration: 500 ng/ml), HER2-Fc antigen (starting concentration: 10 µg/ml), and biopsy 5712 lysate (starting concentrations: 100 µg/ml of total protein and 7 µg/ml of KRT19).
Beads were incubated with phage-sdAb KE32 , anti-CEA, anti-HER2 and anti-KRT19 mouse antibody. Anti-M13 mAb was added, followed by PE-conjugated goat-anti-mouse mAb. 
